Present status and strategy of NSAIDs-induced small bowel injury
- First Online:
- Cite this article as:
- Higuchi, K., Umegaki, E., Watanabe, T. et al. J Gastroenterol (2009) 44: 879. doi:10.1007/s00535-009-0102-2
- 2.2k Downloads
Non-steroidal anti-inflammatory drugs (NSAIDs) are well known to cause gastroduodenal mucosal lesions as an adverse effect. Recently, the serious problem of NSAID-induced small intestinal damage has become a topic of great interest to gastroenterologists, since capsule endoscopy and balloon enteroscopy are available for the detection of small intestinal lesions. Such lesions have been of great concern in clinical settings, and their treatment and prevention must be devised as soon as possible. The prevalence of NSAIDs-induced small intestinal injury is higher than had been expected. Recent studies show that more than 50% of patients taking NSAIDs have some mucosal damage in the small intestine. The gross appearance of NSAID-induced enteropathy varies, appearing variously as diaphragm-like strictures, ulcers, erosions, and mucosal redness. To investigate NSAID-induced enteropathy, and to rule out other specific enteropathies, other useful methods (in addition to capsule endoscopy and balloon enteroscopy) include such modalities as radiological examination of the small intestine, the permeability test, scintigraphy or the fecal excretion test using 111Indium-labeled white blood cells, and measurement of the fecal calprotectin concentration. Diaphragm-like strictures and bleeding from mucosal breaks may be treatable with interventional enteroscopy. Misoprostol, metronidazole, and sulfasalazine are frequently used to treat NSAID-induced enteropathy, but have undesirable effects in some cases. In the experimental model, we confirmed that several existing drugs for gastroduodenal ulcers prevented indomethacin-induced small intestinal injury. Such drugs may be useful for preventing the adverse effects of NSAIDs not only in the stomach but also in the small intestine. We hope to examine these drugs in future clinical studies.
KeywordsNSAIDAspirinSmall intestinal injuryAnti-ulcer drugsCapsule endoscopyBalloon enteroscopy
For a long time, non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin, have been used frequently in clinical settings for their antipyretic, analgesic, and anti-inflammatory effects. NSAIDs are thought to demonstrate such effects by the inhibition of cyclooxygenase (COX), resulting in the inhibition of prostaglandin (PG) production at inflamed sites. But PG also has important roles in maintaining homeostasis of gastrointestinal mucosa. Thus, NSAIDs not only exhibit the expected anti-inflammatory effects but also can cause serious side effects such as gastrointestinal injury . In our aging society, the use of NSAIDs has continued to increase, and their side effect of gastrointestinal mucosal injury has become a clinical problem.
Recently, the serious problem of NSAIDs-induced small intestinal damage has become a topic of great interest to gastroenterologists, since video capsule endoscopy (VCE) and balloon enteroscopy (BE) are available for the detection of small intestinal lesions [2–4]. Such lesions have been of great concern in clinical settings, and their treatment and prevention must be devised as soon as possible. We describe here the present status, pathology, diagnosis, prevention, and treatment of NSAIDs-induced small bowel injury.
Present status of small intestinal mucosal injury caused by NSAIDs and aspirin
Obscure gastrointestinal bleeding
Except small bowel
It seems rational to regard aspirin as an agent that is less toxic to the small intestine in comparison with other NSAIDs because other NSAIDs, but not aspirin, undergo enterohepatic recirculation . Enteric-coated aspirin was originally designed to cause fewer adverse effects on the stomach even when taken for a prolonged period of time. In an attempt to decrease gastroduodenal side effects, the use of enteric-coated aspirin may have shifted the damage to the distal small bowel. In 2007, Leung et al.  reported on follow-up observations using VCE and found small bowel injuries in patients taking low-dose aspirin. This report has received global interest. This notion is further supported in an observational study by Lengeling et al. , who found 40 patients with ileal ulcers, 19 of whom had been taking enteric-coated aspirin. The Japanese Study Group for Double-Balloon Endoscopy (JSG-DBE) established a database for the practical use of DBE in the Japanese population during a 2-year period from 2004 to 2005.  Among 1035 patients registered in the JSE-DBE database, NSAIDs enteropathy occurred in half of the patients taking NSAIDs. Aspirin seems to be less harmful to the small intestine than NSAIDs. In 2008, Watanabe et al.  examined 11 gastric ulcer patients who were taking low-dose aspirin. They used VCE to examine whether or not small-intestinal lesions were present. Diffuse redness was found in 100% (11/11) of the patients, and erosions and ulcers were found in 90.9% (10/11). The very high incidence of damage might be due to the fact that their patients were restricted to individuals who had developed gastric ulcers. Pilotto et al.  recently reported that polymorphisms of CYP2C9, which metabolizes NSAIDs, modify the risk of NSAID-related gastroduodenal bleeding. Therefore, predisposing factors in the patient’s background including genetic differences might increase the susceptibility of the small bowel to aspirin-induced damage. Taking into consideration the widespread use of aspirin in cardiovascular diseases and in cancer chemoprevention, a large-scale study in populations with different backgrounds is needed to standardize the risk for aspirin-induced mucosal damage in the small intestine, as well as in the stomach and the duodenum.
NSAIDs affect the entire gastrointestinal system and cause various abdominal symptoms such as epigastric pain, abdominal pain, constipation, and abdominal distension. In some cases, ulceration can occur in the gastrointestinal region without symptoms due to the analgesic effect of NSAIDs. In the small intestine, typical symptoms include a large amount of blood in the stool due to ulceration, anemia of unknown etiology, and symptoms of obstruction due to diaphragm-like stricture. Clinical presentation of diaphragm disease is nonspecific and may include obstructive symptoms, gastrointestinal blood loss, or abdominal pain [6, 17–19]. It is necessary to pay careful attention to these findings and symptoms in users of aspirin and other NSAIDs.
Pathogenesis of small intestinal mucosal injury caused by NSAIDs and aspirin
PG is involved in regulation of gastrointestinal blood flow and various mucosal functions such as increasing mucus secretion. The decrease in PG production is considered to be the main cause of small bowel injuries due to NSAIDs [20–24]. In a rat study, exogenous PG administration was reported to markedly inhibit small bowel injuries induced by indomethacin, an NSAID .
Bjarnason et al.  proposed a “three hit” hypothesis as explained below. First, NSAIDs solubilize lipids of phospholipids on the mucosal surface, so the epithelial mitochondria are directly damaged. Second, the mitochondrial damage depletes intercellular energy and leads to calcium efflux and to induction of free radicals, a disruption of intercellular junctions occurs, and mucosal permeability increases in the small intestinal mucosa. Third, the mucosal barrier becomes weakened, so bile acid, proteolytic enzymes, intestinal bacteria, or toxins can easily penetrate into the epithelial cells, resulting in mucosal injury.
NSAIDs inhibit mucosal PG synthesis by inhibiting COX activity. There are two types of COX: COX-1 and COX-2. In particular, COX-1 derived PG has been considered important in maintaining homeostasis of intestinal mucosa. Previously, COX-1 inhibition alone was thought to cause a reduction of blood flow in the intestinal mucosa, microcirculatory disturbances, and increased mucosal permeability, in turn resulting in mucosal injury. In recent years, a study using an animal model has shown that small-intestinal mucosal injuries occurred only after both COX-1 and COX-2 were inhibited .
Regarding aspirin, animal experiments have shown that aspirin, even in large doses, do not induce mucosal damages to the stomach despite the inhibition of prostaglandin biosynthesis . Furthermore, the agent has even been shown to be protective against indomethacin-induced small intestinal injury in rats, probably because of its salicylic acid action . Thus, it is impossible to cause small intestinal injuries by aspirin in experimental animals. Enteric-coated aspirin has been developed to prevent gastric damage and dissolves in the proximal small intestine, which might allow aspirin to contact the intestinal mucosa at high concentration. Enteric-coated aspirin might injure the small bowel through a topical irritant effect as well as via the inhibitory effect on COX activity. Further studies including evaluation of the intestinal toxicity of buffered aspirin are needed to support the hypothesis that the enteric-coated formulation of aspirin might be a principal cause of the damage.
Diagnosis of NSAIDs-induced small intestinal injury
The concept and documentation of the underlying disease, namely, NSAID-induced enteropathy, is largely based on measurement of small intestinal permeability and assay of surrogate markers of inflammation, such as fecal calprotectin, in stool . One of the most established noninvasive measures of intestinal permeability is the use of chromium-51-labeled ethylenediaminetetraacetic acid (51Cr-EDTA), which has consistently demonstrated effects of NSAIDs on the small bowel [37–39]. Measurement of inflammation is by qualitative indium-111-labeled neutrophil scintigraphy. In 50% of patients on NSAIDs for more than 6 months, this method of scintigraphy consistently shows accumulation of the labeled white cells on the terminal ileum, halted by the ileocecal valve, after 20 h . The 4-day fecal excretion of 111In also confirms low-level inflammation in NSAID users compared to that in inflammatory bowel disease. About 60–70% of NSAID users have increased 111In excretion, which may persist for up to 16 months after discontinuing NSAIDs . The 111In fecal excretion also correlates well with fecal calprotectin in NSAID-induced disease . However, because of its inaccessibility, more direct assessment of the small bowel, until recently, had been limited to resected specimens or incomplete enteroscopy.
At present, VCE and BE are available for the direct detection of small intestinal lesions. The terminology of enteroscopic findings in NSAID enteropathy has not been standardized. Hayashi et al.  define the criteria of NSAIDs-induced small intestinal injuries: (1) history of NSAID use; (2) endoscopic findings of erosion and/or ulcer and/or typical diaphragm-like strictures; (3) improvement in clinical findings (signs and symptoms) and/or endoscopic findings by cessation of NSAIDs, except for diaphragm disease; and (4) exclusion of other causes (e.g., malignant tumor, inflammatory bowel disease, and infectious disease). However, we cannot check the improvement in endoscopic findings after cessation of NSAIDs because long-term cessation of NSAIDs is frequently impossible for patients with chronic pain or antiplatelet therapy. In the respect of endoscopic findings, those of BE in NSAIDs enteropathy have been variously described as reddish erosions [41, 42], sharply demarcated ulcers in multiplicity [41, 42], or concentric stenoses . In the JSE-DBE database , multiple and discrete ulcers were the most frequent and they were found in 28% of patients in the NSAID group. In an interventional investigation, Maiden et al.  classified the VCE findings into five categories: reddened folds, denuded area, red spot, mucosal break, and blood. By means of VCE, the investigators identified mucosal breaks, which are presumed to conform to discrete ulcers of BE, in 16 of 40 volunteers (40%) after the use of 150 mg/day diclofenac for 2 weeks. Graham et al.  divided VCE findings into red spots, small erosions, large erosions, and ulcers, and they found mucosal lesions in 13 out of 21 patients (62%) with chronic NSAIDs use. While such incidence of erosions and ulcers in the latter investigation may be a consequence of the fact that all patients had been taking non-aspirin NSAIDs, results of Matsumoto et al.  seem to suggest that BE is equal to VCE in the assessment of the severity of NSAIDs enteropathy.
However, the ability to detect small lesions using VCE and BE is not perfect. BE was superior to VCE in the diagnosis of relatively large lesions as polyps. On the other hand, small lesions such erosions and red spots were more often detected by VCE than BE . In addition, we do not know which is higher, the detection ability of biomarkers or that of endoscopy. Further comparison examinations are needed in the respect of clinical usefulness.
Prevention and treatment of small intestinal mucosal injury caused by NSAIDs and aspirin
Intestinal lesions such as those described above have been of great concern in clinical settings, and their treatment and prevention must be devised as soon as possible. The mainstay of treatment for NSAID-induced injury is discontinuation of the NSAIDs. However, even if temporary cessation of the NSAIDs is possible, long-term cessation of NSAIDs is frequently impossible for patients with chronic pain or antiplatelet therapy. And long-term administration of prophylactic drugs is needed for chronic users of NSAIDs or aspirin, especially patients with experience of small intestinal bleeding. Until recently, some trials showed the efficacy of metronidazole, sulfasalazine, and misoprostol for treatment of NSAID-induced injury [45–47]. However, in these studies, efficacy was indirectly evaluated by measuring several markers such as hemoglobin levels and fecal excretion of radiolabeled neutrophils, so their effectiveness has not yet been fully confirmed. Clinically, proton pump inhibitors (PPIs) and prostaglandin analogs are the drugs of first choice for the prevention of NSAID-induced peptic ulcers and bleeding . It is useful to use such drugs as prevent the adverse effects of NSAIDs not only in the stomach but also in the small intestine. However, patients cannot continue to take misoprostol (a prostaglandin analog), since this agent frequently causes adverse effects such as diarrhea, abdominal pain, and bloating.
PPI has a strong inhibitory effect on gastric acid secretion. PPI is also known to have protective effects on gastrointestinal mucosa without the inhibition of acid secretion [58–60]. Such protective effects have been reported to occur via anti-inflammatory effects such as the inhibition of IL-8 production and neutrophil infiltration and via cell injury repair through MAPK [61–63]. The previous studies also found that lansoprazole reduced NSAID-induced small-intestinal mucosal injuries as in our study [64, 65]. NSAIDs induce heme oxygenase-1 (HO-1) and this induction inhibits NSAID-dependent cell death. In addition, lansoprazole has been reported to induce HO-1[1, 66] and thus, HO-1 is thought to be involved in the inhibition of NSAID-associated small bowel injuries. Pretreatment with SnPP, an HO-1 inhibitor, aggravated small bowel injuries induced by indomethacin . On the contrary, pretreatment with both lansoprazole and SnPP clearly aggravated mucosal injuries. We confirmed lansoprazole induced HO-1 in the small intestinal mucosa. These results suggest that lansoprazole, but not omeprazole, ameliorates indomethacin-induced small intestinal ulceration through upregulation of HO-1.
In the clinical studies, Goldstein et al.  examined healthy volunteers who were divided into three groups: celecoxib, naproxen + omeprazole, and control groups. VCE was performed, and the incidence of small-intestinal lesions was 16, 55, and 7%, respectively. The results indicated that small-intestinal lesions could not be prevented by omeprazole. These results were compatible with our experimental results. Evidence of the preventive effects of PPI has already been established for NSAID-induced ulcers in areas affected by gastric acid secretion, such as in the gastroduodenal region. However, enhancement of mucosal protective action which lansoprazole, but not omeprazole, demonstrates is thought to be important in areas not affected by gastric acid, such as the small intestine. For lansoprazole, a clinical trial is needed to confirm our concept.
In another recent clinical examination of prevention using VCE, Niwa et al.  conducted a prospective, double-blind study using a mucosal protective agent, rebamipide, in healthy subjects. These subjects were orally administered diclofenac, omeprazole, and rebamipide for 1 week. After 4 weeks of washout, they were orally administered diclofenac, omeprazole, and placebo for 1 week. Each subject underwent video capsule endoscopy for the evaluation of small-intestinal lesions. When the subjects received a placebo, there were significantly more mucosal injuries in the small intestine, such as erosions and ulcers, compared to when they received rebamipide. Misoprostol co-therapy also reduced the incidence of small-intestinal lesions induced by a 2-week administration of diclofenac sodium in healthy subjects .
For aspirin-induced injury, Watanabe et al.  examined the therapeutic effect of misoprostol. Their subjects were patients with gastric ulcers who were orally taking low-dose, enteric-coated aspirin tablets. They were treated with PPI for 8 weeks. VCE was performed after 8 weeks, and all patients had redness and erosions in the small intestine. Misoprostol was administered instead of PPI for an additional 8 weeks. Then VCE was performed again. Small-intestinal lesions were reported to have improved. Misoprostol showed the ability to induce healing of small bowel injury while the patients continued aspirin administration.
With respect to the type of NSAIDs, Goldstein et al.  reported that 2-week treatment with celecoxib, a selective COX-2 inhibitor, caused less small intestinal injury than treatment with naproxen. Selective COX-2 inhibitors are thus believed to be less injurious than traditional NSAIDs in the small bowel, similar to the stomach. However, Maiden et al.  recently found no difference in the incidence of small intestinal injury between chronic users of traditional NSAIDs and chronic users of selective COX-2 inhibitors. Furthermore, Sugimori et al.  also found the incidence of mucosal breaks in chronic users of preferential COX-2 inhibitors (meloxicam and etodolac) was high, and similar to that in traditional NSAID users. Maiden  speculated the reasons as following. Consequently, selective COX-2 inhibitors may not provide complete protection against some serious gastrointestinal toxicity, such as major bleeding from the lower gastrointestinal tract. The high prevalence of small bowel damage with COX-2 selective agents appears to contradict prevailing theories about the pathogenesis of NSAID-induced gastrointestinal lesions [73, 74]. That they may cause damage may seem counterintuitive as they do not inhibit COX-1 and have no topical effect, in contrast to nonselective NSAIDs. However, it should first be noted that COX-2 selective inhibitors are selective and not exclusive and thus have some COX-1 inhibitory activity also. Second, although considered inducible, COX-2 is also found constitutively in some organs and may have a regulatory role in some tissues, such as altering mucosal blood flow. Third, despite the roles of COX-1 in “housekeeping” and GI mucosal integrity and of COX-2 in inflammation, respectively, COX-1 knockout mice do not develop GI ulceration. COX-1 knockout mice live a relatively normal life and do not develop spontaneous gastrointestinal damage, whereas COX-2 knockout animals have a high mortality in their first 6 months of existence because of small bowel inflammation and perforation [75, 76]. Furthermore, although reduced gastric blood flow is seen in rats exposed to selective COX-1 inhibitors, leukocyte adherence to mesenteric venules is not affected. In contrast, COX-2 inhibition is purported to increase leukocyte adherence without altering blood flow. Only when both isoenzymes are inhibited is gastric mucosal damage seen, suggesting that both reduced mucosal blood flow and increased leukocyte adherence must occur simultaneously for damage to be initiated [75, 77]. These points challenge the dogma that COX-1 inhibition alone causes pathology, as COX-2 may also have a role in gut integrity. Fourth, if patients are naturally low or even deficient in COX-1, then COX-2 selective inhibition will effectively be nonselective. Finally, COX-2 may have an anti-inflammatory role in the vasculature mediating cellular proliferation, adhesion molecule receptor expression, and cytokine release , and so its inhibition may have proinflammatory effects. Further studies with a large sample are needed to resolve whether the beneficial effects of selective COX-2 inhibitors are abolished by their long-term use.
The diaphragm-like stricture is thought to be pathognomonic of NSAID injury, and is likely a scarring reaction secondary to ulcerative injury during long-term NSAIDs use . Clinical presentation of diaphragm disease is nonspecific and may include obstructive symptoms, GI blood loss, or abdominal pain [5–8]. The histological features of the diaphragm-like strictures are fibrosis in the submucosa and thickening of the muscularis mucosa , while the proper muscle layer is intact. Therefore, the risk of intestinal perforation with endoscopic balloon dilation therapy would be low. Endoscopic balloon dilation therapy could be an alternative to surgical intervention for diaphragm disease . Diaphragm disease is now regularly visualized on VCE. However, entrapment of the capsules is common, which requires their retrieval with BE [80, 81] or laparotomy. Intestinal resection was formerly the only option for patients with diaphragm disease in the small bowel.